Rie Aoyama (Singapore)

National University Health System, Singapore Khoo Teck Puat-National University Children's Medical Institute
Dr Rie Aoyama is an Associate Consultant in the Division of Pediatric Infectious Diseases, at Khoo Teck Puat-National University Children's Medical Institute, National University Hospital of Singapore, one of the 2 tertiary pediatric referral centers of the country. She is an undergraduate clinical tutor in pediatrics with the Yong Loo Lin School of Medicine, as well as being heavily involved in post graduate education. Her interests in pediatric infectious diseases include invasive fungal infections, and care of the severely immuno-compromised patients. Out of clinical work, she is actively involved in community outreach projects and strives to empower her patients with health literacy.

Author Of 2 Presentations

Case 1 - SARS-COV-2 Associated Meningoencephalitis in A Child

Date
Thu, 12.05.2022
Session Time
07:00 - 07:50
Session Type
Meet The Experts
Room
DIMITRIS MITROPOULOS HALL
Lecture Time
07:05 - 07:27

MILD COVID-19 INFECTION GENERATES DURABLE ANTIBODY RESPONSES IN UNVACCINATED CHILDREN

Date
Wed, 11.05.2022
Session Time
10:00 - 11:02
Session Type
Oral Presentations Session
Room
BANQUETING HALL
Lecture Time
10:42 - 10:52

Abstract

Backgrounds:

Antibody titres decline in the months following COVID-19 in adults. COVID-19 is typically milder in children and there is limited data on durability of humoral responses following natural infection in this cohort.

Methods:

Children aged ≤17 years old with SARS-CoV-2 infection diagnosed by RT-PCR at our centre were recruited between January and July 2021. Subjects underwent serological testing for anti-Spike and anti-N-capsid Immunoglobulin G (IgG) antibodies at time of diagnosis. Subjects underwent point of care testing (POCT) (ASSURE® SARS-CoV-2 IgG/IgM Rapid Test) for total SARS-CoV-2 IgG at 0-6 weeks post diagnosis. POCT testing was repeated with serological testing and testing for SARS-CoV-2 neutralising antibodies (cPASS™ assay) at 3-6 months, 12 months, and 24 months post-diagnosis. Subjects were allowed to be recruited into the study at any timepoint.

Results:

The results summarise preliminary data for 23 children. Median age of the cohort was 5.9 years (range 8 months -17 years). None were immunosuppressed or had significant co-morbidities. 21 children had a positive household contact. 12 children were asymptomatic at time of diagnosis; all eventually had asymptomatic or mild disease. There were no cases of multisystem inflammatory syndrome in children, or re-infection in the child or their household contacts. 7/18 (39%) children were already seropositive at time of diagnosis on serology testing. On POCT, at 0-6 weeks, 5/6 (83%) children were seropositive; seropositivity persisted in all children at 3-6 months (n=8) and in 5/6 (83%) children at 12 months (figure 1). The study of temporal kinetics for anti-Spike and anti-N-capsid IgG antibodies, and neutralising antibody titres is still ongoing.

figure 1.jpg

Conclusions/Learning Points:

Even mild COVID-19 infection induces durable seroconversion in children with detectable IgG levels at 1 year after infection in the majority.

Hide

Presenter Of 2 Presentations

Case 1 - SARS-COV-2 Associated Meningoencephalitis in A Child

Date
Thu, 12.05.2022
Session Time
07:00 - 07:50
Session Type
Meet The Experts
Room
DIMITRIS MITROPOULOS HALL
Lecture Time
07:05 - 07:27

MILD COVID-19 INFECTION GENERATES DURABLE ANTIBODY RESPONSES IN UNVACCINATED CHILDREN

Date
Wed, 11.05.2022
Session Time
10:00 - 11:02
Session Type
Oral Presentations Session
Room
BANQUETING HALL
Lecture Time
10:42 - 10:52

Abstract

Backgrounds:

Antibody titres decline in the months following COVID-19 in adults. COVID-19 is typically milder in children and there is limited data on durability of humoral responses following natural infection in this cohort.

Methods:

Children aged ≤17 years old with SARS-CoV-2 infection diagnosed by RT-PCR at our centre were recruited between January and July 2021. Subjects underwent serological testing for anti-Spike and anti-N-capsid Immunoglobulin G (IgG) antibodies at time of diagnosis. Subjects underwent point of care testing (POCT) (ASSURE® SARS-CoV-2 IgG/IgM Rapid Test) for total SARS-CoV-2 IgG at 0-6 weeks post diagnosis. POCT testing was repeated with serological testing and testing for SARS-CoV-2 neutralising antibodies (cPASS™ assay) at 3-6 months, 12 months, and 24 months post-diagnosis. Subjects were allowed to be recruited into the study at any timepoint.

Results:

The results summarise preliminary data for 23 children. Median age of the cohort was 5.9 years (range 8 months -17 years). None were immunosuppressed or had significant co-morbidities. 21 children had a positive household contact. 12 children were asymptomatic at time of diagnosis; all eventually had asymptomatic or mild disease. There were no cases of multisystem inflammatory syndrome in children, or re-infection in the child or their household contacts. 7/18 (39%) children were already seropositive at time of diagnosis on serology testing. On POCT, at 0-6 weeks, 5/6 (83%) children were seropositive; seropositivity persisted in all children at 3-6 months (n=8) and in 5/6 (83%) children at 12 months (figure 1). The study of temporal kinetics for anti-Spike and anti-N-capsid IgG antibodies, and neutralising antibody titres is still ongoing.

figure 1.jpg

Conclusions/Learning Points:

Even mild COVID-19 infection induces durable seroconversion in children with detectable IgG levels at 1 year after infection in the majority.

Hide